Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias
- PMID: 12041851
- PMCID: PMC111085
Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias
References
-
- Advisory: Health Canada investigates safety of Meridia (sibutramine). Ottawa: Health Canada; 2002 Mar 27. Available: www.hc-sc.gc.ca/english/protection/warnings/2002/2002_21e.htm (accessed 2002 Apr 17).
-
- Woodman R. Abbott says no link between deaths, obesity drug. Reuters 2002 Mar 15; story ID 707119.
-
- Wolfe SM, Sasich LD, Barbenhenn E. Petition to FDA to ban the diet drug sibutramine (Meridia) [HRG publ no 1613]. Washington: US Food and Drug Administration; 2002 Mar 19. Available (pdf format): www.fda.gov/ohrms/dockets/dailys/02/Mar02/032202/02p-0120_cp00001_vol1.pdf (accessed 2002 Apr 17).
-
- Astrup A, Hansen DL, Lundsgaard C, Toubro S. Sibutramine and energy balance. Int J Obes Relat Metab Disord 1998 Aug;22 Suppl 1:S30-5 - PubMed
-
- Meridia (sibutramine HCl monohydrate, anorexiant-antiobesity). In: Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association; 2002. p. 980-4.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical